Literature DB >> 22765883

Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study.

Margherita Zen1, Nicola Bassi, Linda Nalotto, Mariagrazia Canova, Silvano Bettio, Mariele Gatto, Anna Ghirardello, Luca Iaccarino, Leonardo Punzi, Andrea Doria.   

Abstract

OBJECTIVES: To evaluate disease activity patterns and flare occurrence in a cohort of systemic lupus erythematosus (SLE) patients.
METHODS: Patients registered in our lupus Database, diagnosed with SLE between 1991 and 2004 and followed up quarterly from 2004 to 2010 were considered in the study. Disease activity patterns were defined using SLE Disease Activity Index-2000 (SLEDAI-2K), excluding serology, as follows: clinical quiescent disease (CQD), SLEDAI-2K=0 in the three annual visits; minimal disease activity (MDA), SLEDAI-2K=1 in one or more annual visits; chronic active disease (CAD), SLEDAI-2K≥2 in at least two annual visits; relapsing-remitting disease (RRD), SLEDAI-2K≥2 in one out of 3 annual visits. Flare was defined as an increase in SLEDAI-2K≥4 from the previous visit, according to SELENA-SLEDAI flare index.
RESULTS: One hundred and sixty-five patients fulfilled the inclusion criteria. During the 7 year follow-up, 109 (66%) patients experienced at least one period of active disease (CAD, RRD and MDA), whereas 56 patients (34%) had a persistent CQD. The mean±SD number of patients in each pattern per year was: CAD 52.4±5.8 (31.7%), RRD 16.1±6.8 (9.7%), MDA 9.7±1.7, (5.9%), CQD 87±10.5 (52.6%). Annual flare-rate was 0.19 flare per patient/year and mean±SD number of flares was higher in CAD compared with RRD patients (p<0.01). At the multivariate analysis positive anti-dsDNA antibodies, low C3 or C4, male sex, longer lag time between SLE onset and diagnosis, higher number of flares, and use of immunosuppressant were independently associated with active disease including CAD and RRD patterns.
CONCLUSIONS: Two-thirds of our patients developed at least one period of active disease during the 7-year follow-up despite tight monitoring and standard treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22765883

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  27 in total

Review 1.  Treat to target in systemic lupus erythematosus: a commentary.

Authors:  Manuel F Ugarte-Gil; Paula I Burgos; Graciela S Alarcón
Journal:  Clin Rheumatol       Date:  2016-07-12       Impact factor: 2.980

Review 2.  Galectin-3 in autoimmunity and autoimmune diseases.

Authors:  Felipe L de Oliveira; Mariele Gatto; Nicola Bassi; Roberto Luisetto; Anna Ghirardello; Leonardo Punzi; Andrea Doria
Journal:  Exp Biol Med (Maywood)       Date:  2015-07-03

3.  Long-Term Clinical Outcome in Systemic Lupus Erythematosus Patients Followed for More Than 20 Years: The Milan Systemic Lupus Erythematosus Consortium (SMiLE) Cohort.

Authors:  Maria Gerosa; Lorenzo Beretta; Giuseppe Alvise Ramirez; Enrica Bozzolo; Martina Cornalba; Chiara Bellocchi; Lorenza Maria Argolini; Luca Moroni; Nicola Farina; Giulia Segatto; Lorenzo Dagna; Roberto Caporali
Journal:  J Clin Med       Date:  2022-06-22       Impact factor: 4.964

Review 4.  Clinical guidelines and definitions of autoinflammatory diseases: contrasts and comparisons with autoimmunity-a comprehensive review.

Authors:  M Zen; M Gatto; M Domeneghetti; L Palma; E Borella; L Iaccarino; L Punzi; A Doria
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

Review 5.  New therapeutic strategies in systemic lupus erythematosus management.

Authors:  Mariele Gatto; Margherita Zen; Luca Iaccarino; Andrea Doria
Journal:  Nat Rev Rheumatol       Date:  2019-01       Impact factor: 20.543

6.  Changes of serum IL-6, IL-10 and TNF-α levels in patients with systemic lupus erythematosus and their clinical value.

Authors:  Saiyan Jin; Changcheng Yu; Beiwei Yu
Journal:  Am J Transl Res       Date:  2021-04-15       Impact factor: 3.940

7.  Anti-dsDNA antibody isotypes in systemic lupus erythematosus: IgA in addition to IgG anti-dsDNA help to identify glomerulonephritis and active disease.

Authors:  Danilo Villalta; Nicola Bizzaro; Nicola Bassi; Margherita Zen; Mariele Gatto; Anna Ghirardello; Luca Iaccarino; Leonardo Punzi; Andrea Doria
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

8.  Changes in referral, treatment and outcomes in patients with systemic lupus erythematosus in Germany in the 1990s and the 2000s.

Authors:  Katinka Albrecht; Dörte Huscher; Jutta Richter; Marina Backhaus; Sascha Bischoff; Ina Kötter; Katja Thiele; Angela Zink
Journal:  Lupus Sci Med       Date:  2014-12-12

Review 9.  In-/off-label use of biologic therapy in systemic lupus erythematosus.

Authors:  Mariele Gatto; Emese Kiss; Yaakov Naparstek; Andrea Doria
Journal:  BMC Med       Date:  2014-02-17       Impact factor: 8.775

10.  Health technology assessment of belimumab: a new monoclonal antibody for the treatment of systemic lupus erythematosus.

Authors:  Maria Lucia Specchia; Chiara de Waure; Maria Rosaria Gualano; Andrea Doria; Giuseppe Turchetti; Lara Pippo; Francesco Di Nardo; Silvio Capizzi; Chiara Cadeddu; Flavia Kheiraoui; Luca Iaccarino; Francesca Pierotti; Ilaria Palla; Maria Assunta Veneziano; Daniela Gliubizzi; Antonella Sferrazza; Nicola Nicolotti; Rolando Porcasi; Giuseppe La Torre; Maria Luisa Di Pietro; Walter Ricciardi
Journal:  Biomed Res Int       Date:  2014-08-17       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.